Evommune (EVMN) Operating Income (2024 - 2026)
Evommune's (EVMN) quarterly Operating Income came in at -$24.0 million in Q1 2026, down 59.35% year-on-year from -$58.9 million in Q1 2025, and up 19.39% on a QoQ basis from -$29.7 million in Q4 2025.
Evommune (EVMN) Operating Income (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Operating Income data on file, last reported at -$24.0 million in Q1 2026.
- On a quarterly basis, Operating Income fell 59.35% year-over-year to -$24.0 million in Q1 2026; TTM through Mar 2026 was -$82.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$81.1 million, down 15.79% from the prior year.
- Operating Income for Q1 2026 stood at -$24.0 million, up from -$29.7 million in the prior quarter.
- Over the last five years, Operating Income for EVMN reached as high as -$13.3 million in Q3 2025 and fell as low as -$29.7 million in Q4 2025.
- Historically, Operating Income has averaged -$20.0 million across 3 years, with a median of -$19.0 million in 2024.
- Across the five-year window, Operating Income gained 19.31% in 2025 and slumped 59.35% in 2026, its largest moves.
- Year by year, Operating Income stood at -$21.5 million in 2024, then plunged by 38.51% to -$29.7 million in 2025, then grew by 19.39% to -$24.0 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$24.0 million in Q1 2026, -$29.7 million in Q4 2025, and -$13.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | -23.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.95 Mn |
| Dec 31, 2025 | -29.72 Mn |
| Sep 30, 2025 | -13.33 Mn |
| Mar 31, 2025 | -15.03 Mn |
| Dec 31, 2024 | -21.45 Mn |
| Sep 30, 2024 | -16.52 Mn |